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ABSTRACT
Objectives: To examine the effect of opioid
maintenance treatment (OMT) on somatic morbidity in
a cohort of OMT patients.
Design: Retrospective cohort study.
Setting: OMT programme in two Norwegian counties.
Participants: 200 OMT patients, participation rate
71.2%.
Main outcome measures: Incidence rates (IR)
before, during and after OMT for acute/subacute
hospital-treated somatic disease incidents (drug-
related, non-drug-related, injuries) and rates for
inpatient days and outpatient treatment contacts.
Results: IR for drug-related hospital treatment
episodes were 76% lower during compared to before
OMT (before versus during incidence rate ratio (IRR)
4.2 (95% CI 2.9 to 6.2), p<0.001) and 11 times higher
after compared to during OMT (after versus during IRR
11.1 (6.6 to 18.5), p<0.001). For non-drug-related
treatment episodes, IR were 35% higher during than
before OMT (before versus during IRR 0.7 (0.6 to 1.0),
p¼0.02)and32%higheraftercomparedtoduringOMT
(IRR 1.4 (0.9 to 2.2), p¼0.15), while injuries showed
littlechangeaccordingtoOMTstatus.Althoughpatients
with on-going drug-taking during OMT showed less
reduction in drug-related hospital-treated incidents
duringtreatmentthanpatientsnotusingillicitdrugs,the
quartile with most drug-taking showed a signiﬁcant
reduction (before versus during IRR 3.6 (2.4 to 5.3)).
Patients who had experienced cessation of OMT
showed a signiﬁcant reduction in drug-related
treatment episodes during OMT (before versus during
IRR1.7(1.0to2.9)),althoughlessthanpatientswithout
OMTinterruptions (before versusduringIRR6.1(3.6 to
10.6)), and a signiﬁcant increase after OMT cessation
compared with during OMT (IRR 5.4 (3.0 to 9.7)).
Conclusion: Acute/subacute drug-related somatic
morbidity is reduced during compared to before OMT.
This was also found for patients with on-going drug-
taking during OMT. However, acute drug-related health
problems show an increase after OMT cessation, and
this is a matter of concern. Further studies on somatic
morbidity after OMT cessation should be carried out.
INTRODUCTION
Dependent opioid users, especially those
injecting heroin, have increased somatic
1e3
and psychological morbidity
3e6 and reduced
health-related quality of life.
78Injecting drug
users are prone to chronic bloodborne viral
infections, especially HIV/AIDS
91 0and
chronic hepatitis B
11 and hepatitis C,
11 12 as
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ARTICLE SUMMARY
Article focus
- Opioid maintenance treatment (OMT) is the most
widely used treatment for opioid dependence, but
the effects of OMT on physical health problems
have received relatively little attention.
- This study investigates how acute somatic
morbidity (drug-related, non-drug-related,
injuries) varies according to OMT status
(before, during, after OMT) in a cohort of 200
OMT patients.
- The research questions were: Is somatic
morbidity reduced during OMT compared to
before and after treatment? If so, what types of
disease incidents are reduced? How is the effect
of OMT status on somatic morbidity inﬂuenced
by various patient characteristics?
Key messages
- Acute drug-related somatic morbidity (overdoses,
injecting-related, other) is substantially reduced
during compared to before OMT.
- This was also found for ‘problem patients’ with
on-going drug-taking during OMT, but to a lesser
degree than for patients not using illicit drugs.
Strengths and limitations of this study
Strengths
- Participation rate was high, selection bias limited,
observation period long and the evaluation of
morbidity changes was based on assessment of
full-text hospital records.
Limitations
- The study focused on acute health problems
treated in hospital, but elective hospital contact
due to chronic health problems and primary
healthcare contacts were not included.
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Open Access Researchwell as acute and subacute bacterial infections and other
complications related to injecting.
13 Opioid dependence
is associated with social marginalisation, criminality and
socioeconomic deprivation accompanied by malnutrition,
chronic diseases and generally impaired health as well as
exposure to overdoses and trauma.
1 Mortality among
injecting drug users is much greater than in the general
population, with a standardised mortality ratio ranging
from 5 to 30 in studies from several countries.
10 14 The
main causes of death (in descending order) are overdose,
diseases, trauma and suicide.
10
Maintenance treatment, hereafter called opioid
maintenance treatment (OMT), has been the most
widely used treatment for opioid dependence for the last
number of decades.
15 The speciﬁc changes in physical
and mental health that occur during OMT have received
surprisingly little detailed research attention.
16 Mainte-
nance treatment leads to reduced use of illegal opioids
and less injection.
17 18 It also induces tolerance to
opioids,
19 20 and a corresponding decline in drug-
related morbidity including overdoses should be
expected. Some studies report improved somatic health
during OMT based on interviews,
17 clinical assessment
21
and reduced consumption of inpatient care due to
infections,
22 23 but relatively few studies have investi-
gated OMT-related somatic health effects and morbidity
patterns. In a previous study we found reductions in
somatic disease incidents treated in hospital or by
general practitioners during OMT compared to ‘not in
treatment’.
24 Drug-related incidents were reduced by
about two thirds, but non-drug-related incidents showed
a non-signiﬁcant increase (possibly due to closer contact
with health services) and injuries showed no change
during treatment. These ﬁndings were, however, based
upon a small sample of patients from one municipality.
In order to evaluate the effects of maintenance treat-
ment, it is necessary to study morbidity prior to, during
and after OMT. Such studies are scarce, and very few
include long-term follow-up.
The present study investigates how somatic
co-morbidity varies according to OMT status (before,
during and after OMT) in a group of 200 patients. The
main hypothesis to be tested was that somatic morbidity
is reduced during OMT. More detailed research ques-
tions were: (1) What changes in somatic morbidity are
found during OMT compared to before and after
treatment, and what types of disease incidents are
reduced? and (2) How is the effect of OMT status on
somatic morbidity inﬂuenced by various patient charac-
teristics?
MATERIALS AND METHODS
Design, sample and setting
Methadone and buprenorphine are used as substitution
medications in the national Norwegian OMT
programme, which began in 1998. On 13 December
2009, 5383 people were in treatment, and 55.7% were
receiving methadone and 44.3% buprenorphine.
25
Norway has a population of 4.9 million and the target
group for OMT is estimated to be about 10000.
25
The study has a retrospective cohort design. The
cohort was established in 2007e8 and consists of those
admitted to OMT from 1998 until the end of June 2007
in two counties (Hedmark and Oppland) in Norway
(ﬁgure 1). The participants were recruited through their
treatment contacts. Out of a total of 319 patients who
started OMT, 38 had no contact with local health or
social services at the time of invitation and were
regarded as ineligible for this study. Of the remaining
281, 13 who died after their ﬁrst OMT entry were
included. Among the 268 eligible subjects still alive, 187
consented to participate and 81 did not, and so the
cohort consisted of 200 persons. The participation rate
was 71.2%, 68.8% among patients in treatment versus
73.7% among those not in treatment when invited.
Measures
A somatic disease incident was deﬁned as any acute or
subacute health problem leading to inpatient or outpa-
tient hospital treatment, henceforth called hospital
treatment episodes, treatment episodes or just episodes.
The numbers of hospital treatment episodes, inpatient
days and outpatient hospital contacts were recorded.
Incidence rates and rates of inpatient days and outpa-
tient contacts for the periods before, during and after
OMTwere calculated. Incidence rate ratios before versus
during treatment and after versus during treatment were
estimated. Only records from somatic departments were
examined. Psychiatric disease incidents were only
considered if they caused a somatic condition, for
example due to self-harm. Hospital contacts for chronic
somatic disorders were not included, but acute treat-
ment episodes caused by an underlying chronic disease
were assessed. One episode could lead to more than one
contact, for instance follow-up of a fracture or an
abscess. One episode documented in records from
several hospitals was only counted once. Episodes were
Figure 1 Participants: patients starting opioid maintenance
treatment between 1998 and June 2007. The studied cohort
consists of the 200 included patients.
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other), non-drug-related (infection, other) or injuries.
Data
One hundred and thirty-six of the 187 alive participants
(73%) underwent structured interviews which collected
information on personal data, former hospital contacts
and drug history as well as education and employment
history.
Records from somatic departments in local hospitals
were examined for all participants. Based on interview
information, records from other hospitals were collected
and more than 99% of all requested records were
examined. Only incidents of somatic disease docu-
mented in hospital records were included and records
for all 200 participants were examined.
Data were also drawn from annual status reports on
each patient in the national OMT programme with
information about ongoing drug-taking during OMT
based on urine tests and clinical assessment. A combined
score based on use of illicit opioids, cannabis, benzodi-
azepines and central stimulants during OMT was calcu-
lated for each patient. Data were obtained for 183
participants (91.5%).
Observation period
Data were studied for the 5 years before ﬁrst admittance
to maintenance treatment, up to the ﬁrst 5 years during
OMT (one or consecutive periods), and up to the ﬁrst
5 years out of treatment (one or consecutive periods)
after ﬁrst admittance to OMT. Thus, the post-OMT
period was deﬁned as the sum of the time between
treatment periods and time after the last treatment
period. The total observation period was 1000 patient-
years before, 813 during and 91 after OMT. The date of
collection of their record from the local hospital (during
2008e9) was deﬁned as the study end-point for each
patient.
Inter-rater agreement
Inter-rater agreement was established in the pilot
study.
24 We found high inter-rater reliability for whether
hospital treatment episodes were drug-related (k¼1)
and for categories among drug-related treatment
episodes (overdose, injecting-related or other, k¼0.82).
In this study, IS (the ﬁrst author) ﬁrst scrutinised all
full-text records. Treatment episodes considered difﬁcult
to categorise were discussed between IS and another
physician (the co-author ER) until consensus was
reached.
Statistical analyses
Incidence rates were analysed by means of a Poisson
regression model. Dependencies in the data, due to the
fact that each participant was measured repeatedly
(before, during and after OMT), were handled by
generalised estimating equations with unstructured
working correlation and robust variance estimation.
With regard to drug-related treatment episodes, we
investigated the possible inﬂuence of different patient
characteristics on the effect of OMT by including the
interaction between OMT and the characteristic in
question in the model, one by one. Incidence rate ratios
with 95% CIs were estimated. The signiﬁcance level was
set to 5%. All analyses were performed in SPSS v 15.
The study was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate. Exemption from the duty of conﬁdentiality
and professional secrecy for those who had died was
granted by the Norwegian Directorate of Health.
RESULTS
Cohort characteristics
Sixty-six per cent of the cohort were men and the mean
age at the ﬁrst entry to maintenance treatment was
37 years. Methadone was prescribed to 67% and bupre-
norphine to 33% at the point of entry to the study. Mean
dosage for methadone was 122 mg and 17.6 mg for
buprenorphine. Fifty-one out of 200 (26%) had left
maintenance treatment once or more during the
observation period, while the rest had been in contin-
uous treatment since they were included. Mean age of
ﬁrst use of heroin was 21.1 years, and mean duration of
opioid dependence before OMT was 12.3 years. Thirty-
four per cent reported more than 10 overdoses during
their lifetime, 54% between one and 10, and 12%
reported none. Seventeen per cent had not completed
9 years of compulsory schooling, 50% had completed
9 years and 33% had 12 or more years of education.
Twenty-three per cent had <1 year of employment, 28%
between 1 and 5 years and 49% had more than 5 years of
work experience.
Among the patients who had experienced interruption
of maintenance treatment, 15% were assessed as stable
and drug-free when leaving OMT for the ﬁrst time, while
85% were assessed as unstable and taking drugs.
Changes in hospital-treated somatic disease incidents
Table1showstheratesofhospitaltreatmentepisodesdue
to acute and subacute somatic disease incidents and the
rates for inpatient days and outpatient hospital contacts
for the various categories of episodes before, during and
after OMT. Table 2 displays the statistical signiﬁcance of
these changes by showing the incidence rate ratios
according to different OMT status; before versus during
OMTand after versus during OMT, respectively. A total of
1021 somatic disease incidents were registered: 605
before, 310 during and 106 after OMT.
The rate of all treatment episodes was 37% lower
during compared to the period before treatment (before
versus during OMT incidence rate ratio (IRR) 1.6 (95%
CI 1.3 to 1.9), p<0.001). The rate in the post-OMT
period was 197% higher compared to the period during
OMT (after versus during treatment IRR 2.8 (95% CI 2.1
to 3.9), p<0.001).
During treatment, the rate of all inpatient hospital
treatment days was 38% lower (before versus during
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overall rate of outpatient hospital treatment contacts was
27% lower (before versus during treatment IRR 1.4
(95% CI 1.0 to 1.8), p¼0.04). After treatment the rate of
inpatient days was 5.1 times higher than during treat-
ment (IRR 5.9 (95% CI 3.6 to 9.6), p<0.001) and the
rate of outpatient hospital treatment was 2.6 times
higher (IRR 2.0 (95% CI 1.1 to 3.8), p¼0.03).
Drug-related disease incidents
The rate of drug-related hospital treatment episodes
was 76% lower during treatment than before (before
versus during IRR 4.2 (95% CI 2.9 to 6.2), p<0.001).
The rate of injecting-related episodes was 83% lower
(IRR 5.9 (95% CI 3.1 to 11.4), p<0.001) and the rate of
overdoses was 64% lower (IRR 2.8 (95% CI 1.6 to 5.0),
p<0.001) than before OMT. Among the injecting-related
episodes, local and systemic bacterial infections were the
most common. The rate of drug-related inpatient days
was 84% lower (IRR 6.3 (95% CI 3.4 to 11.8), p<0.001)
and the rate of outpatient contacts was 79% lower during
treatment compared to the pre-treatment period (IRR
4.8 (95% CI 2.7 to 8.3), p<0.001).
The post-OMT rate for drug-related treatment
episodes was higher than the rate before or during
treatment. Compared to the period during OMT,
the rate was 10.1 times higher (IRR 11.1 (95% CI 6.6 to
18.5), p<0.001). Overdoses after OMT were double
those before OMT and the overdose rate was 5.6 times
higher compared to the period during OMT (IRR 5.8
(95% CI 2.7 to 12.3), p<0.001). The rate of injecting-
related episodes was 14.2 times higher after than during
treatment (IRR 12.6 (95% CI 4.3 to 36.8), p<0.001),
the rate of inpatient days due to drug-related episodes
was 23.8 times higher (IRR 25.2 (95% CI 13.1 to 48.7),
p<0.001) and the rate of outpatient contacts was
10.3 times higher (IRR 10.6 (95% CI 4.7 to 25.9),
p<0.001).
Non-drug-related disease incidents
Non-drug-related treatment episodes were 35% more
frequent during treatment compared to the pre-OMT
Table 1 Acute/subacute hospital-treated somatic disease incidents: incidence rates and rates of inpatient days and outpatient
treatment contacts per 100 patient-years
OMT status
Before During After*
Incidence rates
All acute/subacute incidents 60.5 38.1 113.0
All drug-related incidents 31.9 7.5 75.7
Overdoses 10.4 3.7 20.8
Injecting-related, total** 14.2 2.4 34.0
Deep venous thrombosis/lung embolism 0.6 0.2 1.1
Acute hepatitis B and C 0.9 0.1 1.1
Local bacterial infections 8.5 1.5 19.7
Systemic bacterial infections 3.3 0.5 11.0
Other 0.9 0.1 1.1
Other drug-related, total** 7.3 1.4 20.8
Withdrawal-related 2.7 0.5 4.4
Impaired general condition 1.4 0.2 7.7
Neuromuscular 0.5 0.0 1.1
Other 2.7 0.6 7.7
All non-drug-related incidents 12.4 16.7 21.9
Infections 3.7 4.7 11.0
Other 8.7 12.1 11.0
Injuries 16.2 13.9 15.4
Treatment contact rates
Inpatient days per 100 patient-years 150.7 92.4 472.8
Drug-related 86.9 13.9 331.3
Non-drug-related 31.7 62.9 69.1
Injuries 32.1 15.6 72.4
Outpatient contacts per 100 patient-years 56.4 41.4 107.5
Drug-related 22.9 4.8 49.4
Non-drug-related 12.1 16.9 26.3
Injuries 21.4 19.8 31.8
The rates before and during OMT refer to all patients, while the rates after OMT refer exclusively to patients with interrupted OMT. Patient-years
at risk: 1000 before, 813 during and 91 after OMT. Number of incidents: 605 before, 310 during and 106 after OMT.
*After OMT is deﬁned as time out of treatment (one or more consecutive periods) after ﬁrst admittance to OMT, that is the sum of the time
between treatment periods and time after the last treatment period.
**Subgroups in italic.
OMT, opioid maintenance treatment.
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p¼0.02) and both infections and other non-drug-related
episodes increased. After treatment there was a 31%
increase for all non-drug-related episodes versus the
period during OMT (IRR 1.4 (95% CI 0.9 to 2.2),
p¼0.15). The rates for inpatient days and outpatient
hospital treatment contacts showed similar changes.
Injuries
The changes in incidence and treatment contact rates
for injuries were minor and non-signiﬁcant.
Interaction between OMT status and patient characteristics
From the data in table 1 it is evident that changes
according to OMT status in the total number of hospital
treatment episodes are associated with changes in drug-
related treatment episodes. In the analysis of how the
effect of OMT status is inﬂuenced by various patient
characteristics, we therefore concentrated on drug-
related episodes alone. Table 3 shows the interaction
between the effect of maintenance treatment (OMT
status) and various patient characteristics, that is the
incidence rate ratio between the periods before and
during OMT for drug-related treatment episodes
adjusted for these characteristics.
In a comparison of patients who received continuous
maintenance treatment throughout the during-OMT
observation period versus those who left treatment once
or more, those with continuous treatment showed
greater incidence rate reduction during treatment than
those with interrupted treatment, although the latter still
showed signiﬁcant reduction versus the pre-treatment
period. After treatment, the group with interrupted
treatment showed an increase, with the incidence rate
ratio between the periods after and during OMT for this
group being 5.4 (3.0 to 9.7) (not shown in the table).
Patients with ongoing illicit drug-taking during OMT
showed less reduction in incidence rate during treat-
ment than patients not using illicit drugs. Even so, the
quartile taking most drugs showed a signiﬁcant reduc-
tion during versus before OMT (before versus during
IRR ratio 3.6 (2.4 to 5.3)).
Among the pre-OMT patient characteristics, only
employment history and years of opioid dependence
before OMT showed a signiﬁcant interaction with OMT
status in the period before versus during OMT. Individ-
uals with less work experience and fewer years of opioid
dependence, respectively, showed less reduction in inci-
dence rates during compared to before treatment.
Interaction was also tested for gender, age at OMT start,
lifetime number of overdoses, years of education and
age at heroin debut without showing any statistically
signiﬁcant interaction (p>0.1).
DISCUSSION
The study shows a substantial reduction in drug-related
hospital-treated incidents of somatic disease during
maintenance treatment compared to the pre-treatment
period. The reduction consists of less overdoses, and
fewer injecting-related and other drug-related treatment
episodes.
Overdoses are the most frequent cause of death among
dependent opioid users,
10 and the 64% reduction in
overdoses during treatment is an important ﬁnding.
Several studies have documented reduced mortality
during OMT compared to the pre-OMT period
92 6 e32
and after leaving OMT,
33e35 and the reduction in over-
doses found in the present study supports previous
ﬁndings of reduced mortality during OMT.
Table 2 Acute/subacute hospital-treated somatic disease
incidents: crude incidence rate ratios and treatment contact
rate ratios of inpatient days and outpatient hospital contacts
IRR/TCRR (95% CI) p Value
Before versus during OMT, during OMT as reference
(incidence rate[1)
All incidents 1.6 (1.3 to 1.9) <0.001
Drug-related* 4.2 (2.9 to 6.2) <0.001
Overdoses 2.8 (1.6 to 5.0) <0.001
Injecting-related 5.9 (3.1 to 11.4) <0.001
Other 5.7 (2.8 to 11.9) <0.001
Non-drug-related 0.7 (0.6 to 1.0) 0.02
Injuries 1.2 (0.9 to 1.5) 0.23
Inpatient days
Drug-related 6.3 (3.4 to 11.8) <0.001
Non-drug-related 0.5 (0.3 to 1.0) 0.04
Injuries 2.1 (0.7 to 5.7) 0.17
All 1.7 (1.1 to 2.4) 0.01
Outpatient contacts
Drug-related 4.8 (2.7 to 8.3) <0.001
Non-drug-related 0.7 (0.4 to 1.2) 0.18
Injuries 1.1 (0.7 to 1.6) 0.78
All 1.4 (1.0 to 1.8) 0.04
After versus during OMT, during OMT as reference
(incidence rate[1)
All incidents 2.8 (2.1 to 3.9) <0.001
Drug-related 11.1 (6.6 to 18.5) <0.001
Overdoses 5.8 (2.7 to 12.3) <0.001
Injecting-related 12.6 (4.3 to 36.8) <0.001
Other 16.7 (6.5 to 42.7) <0.001
Non-drug-related 1.4 (0.9 to 2.2) 0.15
Injuries 0.8 (0.3 to 1.8) 0.57
Inpatient days
Drug-related 25.2 (13.1 to 48.7) <0.001
Non-drug-related 1.1 (0.5 to 2.3) 0.78
Injuries 4.6 (0.8 to 28.5) 0.98
All 5.9 (3.6 to 9.6) <0.001
Outpatient contacts
Drug-related 10.6 (4.7 to 25.9) <0.001
Non-drug-related 1.6 (0.7 to 3.7) 0.26
Injuries 1.1 (0.4 to 3.1) 0.87
All 2.0 (1.1 to 3.8) 0.03
The incidence rate ratios indicate the statistical signiﬁcance of the
changes in incidence rates demonstrated in table 1, estimated by
Poisson regression (generalised estimating equations). Patient-
years at risk: 1000 before, 813 during and 91 after OMT. Number of
incidents: 605 before, 310 during and 106 after OMT.
IRR, incidence rate ratios; OMT, opioid maintenance treatment;
TCRR, treatment contact rate ratios.
*Subgroups in italic.
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substantially reduced (by 83%) during OMT. This may
have been due to those OMT patients who stopped
injecting and to others who continued to inject but at
a less frequent rate than before treatment.
28 The
reduction includes all kinds of injecting-related episodes
among which local and systemic bacterial infections are
by far the most frequent. The local skin infections often
require surgical treatment and may give rise to severe
systemic infections as septicaemia, fasciitis, endocarditis,
osteomyelitis, discitis and others. Most of these condi-
tions are rare, but they are much more frequent among
injecting drug users than among the general popula-
tion.
36 Such infections may be life-threatening and may
result in severe and permanent health problems, and
often necessitate complex, long-lasting and expensive
hospital treatment. When injecting-related health prob-
lems among drug users are considered, these apparently
less serious conditions are often overshadowed by the
focus on HIV and hepatitis C. However, some studies
indicate that the burden on the healthcare system due to
injecting-related local and systemic bacterial infections
may be even greater than that due to bloodborne
infections.
37 The present study found that such bacterial
infections were frequent among dependent opioid users
and that they were substantially reduced during main-
tenance treatment.
Non-drug-related treatment episodes were found
to increase (by 35%) during OMT as compared to the
pre-OMT period. Inpatient days increased by 98% and
outpatient treatment contacts increased by 40%. The
reason for this may be closer contact with health services
during maintenance treatment. Within the OMT
programme, patients may receive healthcare that was not
previously available to them, leading to the diagnosis
and treatment of health problems that were previously
not identiﬁed.
38 If so, this increase in non-drug-related
episodes may reﬂect improved access to health services
and not an increase in morbidity. It is theoretically
possible that this increase is due to adverse effects of
OMT, but we have found no evidence of this in our
scrutiny of the hospital records.
Drug-related treatment episodes and related inpatient
days and outpatient hospital contacts were more
frequent in the period after OMT compared to the
periods before OMTand during OMT. These rates apply
only to those patients who had left OMT. Although some
patients may remain drug-free after leaving OMT, it is
likely that many leave OMT, voluntarily or involuntarily,
because of ongoing drug-taking, opposition to
programme rules and control measures, or instability in
taking their OMT medication.
10 25 31 Our data show that
only 15% of those who left OMT were assessed as stable
and drug-free at the time of leaving treatment. Patients
with interrupted maintenance treatment may therefore
constitute a patient subgroup with higher levels of risk-
taking behaviour and/or more serious health problems,
and the post-OMTresults may be inﬂuenced by selection
bias. We therefore examined the interaction between
OMT status (incidence rates before versus during OMT)
and OMT cessation (having experienced OMT cessation
or not) and found less reduction in drug-related treat-
ment episodes in the cessation group compared to the
group with continuous treatment Nevertheless, even the
cessation group experienced a signiﬁcant reduction in
episodes of about 40%. After OMT cessation, however,
Table 3 Acute/subacute drug-related hospital-treated somatic disease incidents: interaction effect between OMT status
(before versus during OMT) and patient characteristics
Patient characteristics p Value for interaction Adjusted IRR (95% CI)
During-treatment characteristics
Interruption of OMT 0.001
Continuous treatment 6.1 (3.6 to 10.6)
Interrupted treatment 1.7 (1.0 to 2.9)
Drug-use during OMT (illicit opioids, cannabis,
benzodiazepines, central stimulants)
0.07
25th Percentile, quartile without drug use 6.5 (3.5 to 12.0)
75th Percentile, quartile with most drug use 3.6 (2.4 to 5.3)
Pre-treatment characteristics
Employment years 0.02
<1 year 2.6 (1.3 to 5.2)
1e5 years 4.1 (1.8 to 9.2)
>5 years 5.5 (2.7 to 11.2)
Opioid dependence before OMT, years 0.01
8 years (25th percentile) 3.3 (2.0 to 5.5)
16 years (75th percentile) 5.4 (3.1 to 9.4)
Adjusted incidence rate ratios (IRR) estimated by Poisson regression (generalised estimating equations) before versus during OMT, during
OMT as reference (incidence rate¼1). Only characteristics showing signiﬁcant interaction with OMT status are shown. Crude IRR are shown in
table 2. Interaction was also tested for gender, age at OMT start, lifetime number of overdoses, years of education and age at heroin debut
without showing signiﬁcant interaction (p>0.1).
Patient-years at risk: 1000 before, 813 during and 91 after OMT. Number of incidents: 605 before, 310 during and 106 after OMT.
IRR, incidence rate ratio; OMT, opioid maintenance treatment.
6 Skeie I, Brekke M, Gossop M, et al. BMJ Open 2011;1:e000130. doi:10.1136/bmjopen-2011-000130
Changes in somatic disease incidents during opioid maintenance treatmentthey experienced a more than ﬁvefold increase
compared to the period during OMT. The high post-
OMT incidence rates, therefore, reﬂect an increase in
acute drug-related health problems after OMT cessation
among patients with treatment interruption, and cannot
be fully explained by selection effects. This is an
important ﬁnding that should stimulate increased
efforts to study the health effects of OMT cessation
and to improve responses to minimise the harmful
consequences.
Even the quartile taking most illegal drugs during
OMTshowed a signiﬁcant 72% reduction in drug-related
treatment episodes during versus before treatment. This
indicates that not only patients with successful mainte-
nance treatment, but also patients with poor rehabilita-
tion results experience health improvement during OMT.
The present study focuses on acute/subacute hospital
treatment episodes. Injecting drug users experience
increased chronic morbidity that reduces their quality of
life
8 39 40 and some studies based on interviews
41 and
clinical assessment
21 show a reduction in chronic health
problems during OMT. However, considering the high
mortality rate among injecting drug users,
10 the often
life-threatening acute disease incidents comprise
a substantialdand perhaps the most importantdpart of
the morbidity pattern within this group.
The study has some limitations. First, the study
assessed acute/subacute hospital-treated disease inci-
dents and not morbidity as such. A key question is
whether changes in incidence and treatment rates
according to OMT status (before, during and after
OMT) reﬂect a change in morbidity; in other words,
whether these rates can be regarded as a proxy indicator
for morbidity. Information on hospital treatment outside
the local area was based on patient recall and some
disease incidents prior to treatment may have been
overlooked. In addition, closer contact with health
services during OMT probably increases patients’ help-
seeking, resulting in hospital treatment for health
problems that would not have been treated before OMT.
Further, the patients were 5 years older during than
before OMT, resulting in an age-dependent increase in
morbidity. Even so, we found a signiﬁcant reduction in
treatment episodes during OMT. Therefore, our ﬁnd-
ings most probably reﬂect a ‘true’ reduction in acute/
subacute incidents of somatic disease, and hence in
acute/subacute somatic morbidity, during compared to
before OMT.
Another limitation is that primary healthcare contacts
were not included in this study. In our previous study,
24
however, general practitioner contacts were registered
and we found that about 80% of all acute somatic disease
incidents assessed as severe resulted in hospital treat-
ment both before and during OMT. The focus on
hospital treatment episodes should therefore provide an
adequate assessment of OMT-related changes in severe
acute health problems within the cohort. Also, the
cohort is relatively old, with a mean age at ﬁrst OMT
entry of 37 years and mean duration of opioid depen-
dence before the ﬁrst admission to OMT of 12 years.
This reﬂects the late introduction of OMT to Norway in
1998 with an accumulated demand for maintenance
treatment by older patients at programme start and
a high recommended age limit for OMT admittance
during the ﬁrst years.
42 The cohort is typical of Norwe-
gian OMT patients, but the age distribution is no doubt
characterised by speciﬁc historical traits of the Norwe-
gian OMT programme and this might be a possible
limitation to the external validity of the study. However,
we did check the effect modiﬁcation of age at OMTentry
(no signiﬁcant interaction) and duration of opioid
dependence before ﬁrst OMT entry (less reduction
among patients with fewer years of dependence) on the
rates of drug-related treatment episodes before versus
during OMT.
Yet another limitation is that the list of diagnoses to
differentiate whether treatment episodes were drug-
related or not has not been validated by external
researchers and we could ﬁnd no similar list in the
literature. There may be some uncertainty about
whether some episodes were drug-related or not;
however, inter-rater reliability scores were high. There
were also analytical problems due to the fact that the
post-OMT observation period was only 91 years versus
1000 before and 813 during OMT. This is mainly due to
the high retention in OMT in Norway. The relatively few
post-OMT years at risk is a limitation in the study, but
with this design and the given retention in treatment,
the post treatment period will nevertheless be unbal-
anced compared to the periods before and during OMT.
The study also has certain strengths. These include the
high participation rate among patients in as well as out
of maintenance treatment at the time of invitation, the
access to all hospital records and the long observation
period. The overall participation rate was high (71%)
and more than 99% of requested hospital records were
obtained. Hence, selection bias was probably of limited
importance in the study. Further, the evaluation of
morbidity changes is based on in-depth assessment of
full-text hospital records which could be expected to give
more robust data than interview data or register data
alone.
Despite possible limitations in the study design, the
ﬁndings document a substantial reduction in acute and
subacute drug-related disease incidents leading to
hospital treatment during OMT compared to the period
before OMT. This reduction in somatic morbidity during
treatment seems also to be valid for patients with on-
going drug-taking during OMT. However, acute drug-
related health problems show an increase after OMT
cessation, and this is a matter of concern. Further studies
on somatic morbidity after OMT cessation should be
carried out.
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